Celcuity Inc. (CELC)

Celcuity's stock has been impacted by several events in the past six months. The Phase 3 VIKTORIA-1 trial achieved its primary endpoint, leading to a stock price surge. The FDA accepted Celcuity's NDA for gedatolisib and granted it Priority Review, setting a PDUFA goal date of July 17, 2026. Celcuity released its Q4 and full year 2025 financial results, reporting a narrower-than-expected loss. Analyst firms have maintained or raised their ratings and price targets for CELC. Recent insider selling by two directors has been noted. Celcuity's stock has delivered a significant change of 1,191.23% over the past year.

As a clinical-stage biotechnology company without approved commercial products, demand seasonality is not applicable to Celcuity. The company's financial performance is primarily driven by progress in clinical trials, regulatory milestones, and its ability to secure capital.

Celcuity, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing targeted therapies for solid tumor indications. Their lead product candidate is gedatolisib, a pan-PI3K and mTORC1/2 inhibitor in late-stage clinical development, particularly for HR+/HER2- advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also has the CELsignia functional cell-signaling platform, a diagnostic technology to match patients to targeted therapies. As a pre-revenue developer, Celcuity's performance is driven by clinical execution, regulatory progress, manufacturing readiness, and access to capital.

Celcuity is headquartered in Minneapolis, Minnesota, United States. Its international footprint is mainly expressed through multinational clinical trial infrastructure and outsourced manufacturing operations.

Celcuity's brand reputation appears to be largely positive, driven by promising clinical trial results and strong analyst support. The company is seen as an innovator in the biotechnology sector, with gedatolisib showing significant potential in targeted oncology. Positive outcomes from the Phase 3 VIKTORIA-1 trial and the FDA's grant of Priority Review for gedatolisib have generated considerable investor enthusiasm and optimism.

Celcuity Inc. has 258 institutional owners and shareholders including Baker Bros. Advisors Lp, NEA Management Company, LLC, and Perceptive Advisors Llc. Some individual investors, such as Lance G. Laing and Brian F. Sullivan, are also listed as major shareholders.